Switch studies in virologically suppressed patients

Switch to LPV/r monotherapy
Pilot Study: Switch to LPV/r monotherapy
Original article : HIV Clin Trials. 2006 Sep-Oct;7(5):237-45 – G Pierone
Last update : 28/03/2014

Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK

  • Pilot study of LPV/r monotherapy suggests maintaining virological success with switch in the majority of patients

Design :

Primary endpoint :

  • Proportion of patients with HIV-1 RNA < 75 c/mL at W48
  • Virologic failure = 2 consecutive HIV-1 RNA > 400 c/mL

  • Median of prior ARV therapy was 122 weeks
    • EFV: 22%
    • NVP: 78%
  • Median CD4 cell count/mm3 at inclusion = 272 ; at nadir = 177
  • 5 patients discontinued before W48
    • 3 for diarrhoea
    • 2 for virologic failure (no emergence of resistance)
  • HIV-1 RNA < 75 c/mL at W48: 12/18 patients (66%), 12/13 who completed 48 weeks of follow-up
  • Adverse events: 2 patients developed diabetes mellitus, 7 required introduction or increase in lipid-lowering agents

 

Back to Table of Contents

Copyright AEI 2017 | Links | Contact | Faculty and Disclosure | Terms of use aei